Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors.

R Sawaya, V K Puduvalli

Journal: Journal of neuro-oncology 2001;50(1-2):189-200

PMID: 11245279

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

The poor prognosis of patients with malignant brain tumors in spite of aggressive multimodality therapy has led to the search for novel therapeutic strategies. Among the targets for such treatment approaches, tumor angiogenesis has captured the attention of not only the medical field but also of the lay public because of its conceptual departure from traditional methods of cancer therapy. Angiogenesis and vascular proliferation are particularly important in the growth and progression of malignant gliomas and are used as indicators of the degree of malignancy. Recent studies have helped us gain a better understanding of the molecular mediators of this process. It is now evident that after the initial formation of malignancy the continued growth of a glioma is critically dependent on its angiogenic potential. Hence, several approaches to control angiogenesis are being developed and tested. In the present review, we examine some of these approaches from a therapeutic perspective and summarize the findings from early human trials of such agents.

Address: Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. [email protected]

DOI: 10.1023/a:1006469830739

Link outs

Free resources

Medical:

https://medlineplus.gov/braintumors.html

Subscription / membership required

Full Text Sources:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linko...

MeSH Terms: Angiogenesis Inhibitors, Angiostatins, Brain Neoplasms, Cell Hypoxia, Cell Movement, Clinical Trials as Topic, Collagen, Cyclohexanes, Endostatins, Endothelial Growth Factors, Endothelium, Vascular, Genetic Therapy, Glioma, Humans, Integrins, Interferons, Lymphokines, Matrix Metalloproteinase Inhibitors, Neoplasm Proteins, Neovascularization, Pathologic, O-(Chloroacetylcarbamoyl)fumagillol, Peptide Fragments, Plasminogen, Prognosis, Receptor Protein-Tyrosine Kinases, Receptor, TIE-2, Retinoids, Sesquiterpenes, Stilbenes, Thalidomide, Tumor Necrosis Factor-alpha, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factors